Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies Milo GattiFabrizio De PontiFederico Pea Review Article Open access 18 April 2021 Pages: 345 - 384
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis Reshmi RoyAlaa A. AlotaibiMark S. Freedman Review Article 02 April 2021 Pages: 385 - 402
Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions Jonathan R. YoungAdare YanagiharaScott H. Kollins Review Article 26 March 2021 Pages: 403 - 424
Pharmacotherapy for Frontotemporal Dementia Rita KhouryYu LiuGeorge T. Grossberg Review Article 11 April 2021 Pages: 425 - 438
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report Emma MortonVenkat Bhatthe CAN-BIND Investigator Team Original Research Article 16 April 2021 Pages: 439 - 450
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study Arnold P. M. van der LeeIbrahim ÖnsesverenNiels C. L. Mulder Original Research Article Open access 10 April 2021 Pages: 451 - 460
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program Olivier CorbeilStéphanie CorbeilMarc-André Roy Original Research Article 13 March 2021 Pages: 461 - 468